2019 Q4 Form 10-K Financial Statement
#000119312520071545 Filed on March 12, 2020
Income Statement
| Concept | 2019 Q4 | 2019 | 2018 Q4 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | -100.0% | ||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $3.370M | $18.13M | $2.730M |
| YoY Change | 23.44% | 14.46% | -45.07% |
| % of Gross Profit | |||
| Research & Development | $4.890M | $4.417M | $2.570M |
| YoY Change | 90.27% | -89.43% | -77.77% |
| % of Gross Profit | |||
| Depreciation & Amortization | $340.0K | $340.0K | |
| YoY Change | 17.65% | ||
| % of Gross Profit | |||
| Operating Expenses | $8.260M | $70.96M | $5.300M |
| YoY Change | 55.85% | 23.14% | -67.94% |
| Operating Profit | -$70.96M | ||
| YoY Change | 117.51% | ||
| Interest Expense | $250.0K | $1.000K | $430.0K |
| YoY Change | -41.86% | -75.0% | 59.26% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $0.00 | $1.517M | -$10.00K |
| YoY Change | -100.0% | 46.01% | |
| Pretax Income | -$8.100M | -$67.31M | -$4.890M |
| YoY Change | 65.64% | 639.05% | -69.94% |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$8.100M | -$69.44M | -$4.890M |
| YoY Change | 65.64% | 119.86% | -69.94% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$232.6K | -$2.569M | -$207.7K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 38.33M | 23.54M shares | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2019 Q4 | 2019 | 2018 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $143.1M | $143.1M | $76.90M |
| YoY Change | 86.09% | 86.09% | -28.86% |
| Cash & Equivalents | $143.1M | $143.1M | $76.93M |
| Short-Term Investments | $0.00 | ||
| Other Short-Term Assets | $503.0K | ||
| YoY Change | |||
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | $500.0K | $500.0K | $200.0K |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $143.6M | $143.6M | $77.17M |
| YoY Change | 86.09% | 86.01% | -29.09% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $2.060M | $2.800M | $400.0K |
| YoY Change | 415.0% | 600.0% | -55.8% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $30.00K | $0.00 | $100.0K |
| YoY Change | -70.0% | -100.0% | -83.33% |
| Total Long-Term Assets | $3.427M | $3.400M | $453.0K |
| YoY Change | 656.51% | 750.0% | -69.88% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $143.6M | $143.6M | $77.17M |
| Total Long-Term Assets | $3.427M | $3.400M | $453.0K |
| Total Assets | $147.0M | $147.0M | $77.62M |
| YoY Change | 89.42% | 89.43% | -29.65% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $4.100M | $1.600M | $4.600M |
| YoY Change | -10.87% | 128.57% | -58.18% |
| Accrued Expenses | $600.0K | $3.100M | |
| YoY Change | -20.51% | ||
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $100.0K | $100.0K | |
| YoY Change | |||
| Total Short-Term Liabilities | $4.743M | $4.700M | $4.627M |
| YoY Change | 2.51% | 2.17% | -57.77% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $100.0K | $100.0K | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $400.0K | $400.0K | $319.0K |
| YoY Change | 25.39% | 33.33% | -34.36% |
| Total Long-Term Liabilities | $500.0K | $500.0K | $319.0K |
| YoY Change | 56.74% | 66.67% | -34.36% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $4.743M | $4.700M | $4.627M |
| Total Long-Term Liabilities | $500.0K | $500.0K | $319.0K |
| Total Liabilities | $5.336M | $5.300M | $4.946M |
| YoY Change | 7.89% | 8.16% | -56.77% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$299.5M | -$230.1M | |
| YoY Change | 30.18% | 15.91% | |
| Common Stock | $0.00 | $0.00 | |
| YoY Change | |||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $141.7M | $141.7M | $72.67M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $147.0M | $147.0M | $77.62M |
| YoY Change | 89.42% | 89.43% | -29.65% |
Cashflow Statement
| Concept | 2019 Q4 | 2019 | 2018 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$8.100M | -$69.44M | -$4.890M |
| YoY Change | 65.64% | 119.86% | -69.94% |
| Depreciation, Depletion And Amortization | $340.0K | $340.0K | |
| YoY Change | 17.65% | ||
| Cash From Operating Activities | -$4.630M | -$15.39M | -$9.780M |
| YoY Change | -52.66% | -51.25% | -15.76% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$780.0K | $879.0K | $0.00 |
| YoY Change | 1693.88% | -100.0% | |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $0.00 | $190.0K | $0.00 |
| YoY Change | -99.66% | -100.0% | |
| Cash From Investing Activities | -$780.0K | -$688.0K | $0.00 |
| YoY Change | -101.23% | -100.0% | |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $80.70M | $81.04M | |
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 82.21M | $82.24M | 0.000 |
| YoY Change | 14327.54% | -100.0% | |
| NET CHANGE | |||
| Cash From Operating Activities | -4.630M | -$15.39M | -9.780M |
| Cash From Investing Activities | -780.0K | -$688.0K | 0.000 |
| Cash From Financing Activities | 82.21M | $82.24M | 0.000 |
| Net Change In Cash | 76.80M | $66.17M | -9.780M |
| YoY Change | -885.28% | 165.77% | -298.78% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$4.630M | -$15.39M | -$9.780M |
| Capital Expenditures | -$780.0K | $879.0K | $0.00 |
| Free Cash Flow | -$3.850M | -$16.27M | -$9.780M |
| YoY Change | -60.63% | -48.55% | -15.69% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2018Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
76928000 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2060000 | |
| CY2018Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
400000 | |
| CY2019Q4 | us-gaap |
Assets
Assets
|
147023000 | |
| CY2019Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
770000 | |
| CY2019Q4 | nltx |
Prepayments And Deposits Noncurrent
PrepaymentsAndDepositsNoncurrent
|
30000 | |
| CY2018Q4 | nltx |
Prepayments And Deposits Noncurrent
PrepaymentsAndDepositsNoncurrent
|
53000 | |
| CY2018Q4 | us-gaap |
Assets
Assets
|
77618000 | |
| CY2019Q4 | us-gaap |
Assets Current
AssetsCurrent
|
143596000 | |
| CY2018Q4 | us-gaap |
Assets Current
AssetsCurrent
|
77165000 | |
| CY2019Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
143093000 | |
| CY2019Q4 | nltx |
Receivables Prepayments And Deposits Current
ReceivablesPrepaymentsAndDepositsCurrent
|
503000 | |
| CY2018Q4 | nltx |
Receivables Prepayments And Deposits Current
ReceivablesPrepaymentsAndDepositsCurrent
|
237000 | |
| CY2019Q4 | us-gaap |
Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
|
4125000 | |
| CY2018Q4 | us-gaap |
Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
|
4618000 | |
| CY2019Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
441216000 | |
| CY2018Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
302759000 | |
| CY2019Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
||
| CY2019Q4 | us-gaap |
Liabilities
Liabilities
|
5336000 | |
| CY2018Q4 | us-gaap |
Liabilities
Liabilities
|
4946000 | |
| CY2019Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
147023000 | |
| CY2018Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
77618000 | |
| CY2019Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
4743000 | |
| CY2018Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
4627000 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
556000 | |
| CY2019Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-299529000 | |
| CY2018Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-230087000 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
141687000 | |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
72672000 | |
| CY2019 | nltx |
Research And Development Excluding Acquired In Process Research And Development
ResearchAndDevelopmentExcludingAcquiredInProcessResearchAndDevelopment
|
4417000 | |
| CY2018 | nltx |
Research And Development Excluding Acquired In Process Research And Development
ResearchAndDevelopmentExcludingAcquiredInProcessResearchAndDevelopment
|
41789000 | |
| CY2017 | nltx |
Research And Development Excluding Acquired In Process Research And Development
ResearchAndDevelopmentExcludingAcquiredInProcessResearchAndDevelopment
|
36267000 | |
| CY2019 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
18826000 | |
| CY2018 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
15835000 | |
| CY2017 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
14852000 | |
| CY2019 | us-gaap |
Operating Expenses
OperatingExpenses
|
70959000 | |
| CY2018 | us-gaap |
Operating Expenses
OperatingExpenses
|
57624000 | |
| CY2017 | us-gaap |
Operating Expenses
OperatingExpenses
|
51119000 | |
| CY2019 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-69442000 | |
| CY2018 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-31585000 | |
| CY2017 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-50183000 | |
| CY2017 | us-gaap |
Profit Loss
ProfitLoss
|
-50183000 | |
| CY2019 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
66165000 | |
| CY2018 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
24896000 | |
| CY2019 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
10000 | |
| CY2018 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-48000 | |
| CY2019 | us-gaap |
Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
|
-2244000 | |
| CY2018 | us-gaap |
Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
|
-6472000 | |
| CY2019 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-15394000 | |
| CY2018 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-31577000 | |
| CY2019 | us-gaap |
Proceeds From Interest Received
ProceedsFromInterestReceived
|
1544000 | |
| CY2019 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-69442000 | |
| CY2018 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-31515000 | |
| CY2017 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-50084000 | |
| CY2019 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.57 | |
| CY2018 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.34 | |
| CY2017 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.14 | |
| CY2019 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
27030355 | |
| CY2018 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
23519508 | |
| CY2017 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
23450315 | |
| CY2019 | nltx |
Increase Decrease In Receivables Prepayments And Deposits
IncreaseDecreaseInReceivablesPrepaymentsAndDeposits
|
-290000 | |
| CY2019 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-263000 | |
| CY2018 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-452000 | |
| CY2019 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
7683000 | |
| CY2018 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
4698000 | |
| CY2018 | nltx |
Increase Decrease In Receivables Prepayments And Deposits
IncreaseDecreaseInReceivablesPrepaymentsAndDeposits
|
-1041000 | |
| CY2017 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-349000 | |
| CY2017 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
3839000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
76928000 | |
| CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
52032000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
143093000 | |
| CY2018 | us-gaap |
Proceeds From Interest Received
ProceedsFromInterestReceived
|
1684000 | |
| CY2019 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
879000 | |
| CY2019 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-688000 | |
| CY2018 | us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
56000000 | |
| CY2018 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
49000 | |
| CY2018 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
55951000 | |
| CY2019 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
1555000 | |
| CY2018 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
602000 | |
| CY2019 | us-gaap |
Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
|
9000 | |
| CY2018 | us-gaap |
Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
|
32000 | |
| CY2019 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
82237000 | |
| CY2018 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
570000 | |
| CY2017 | nltx |
Increase Decrease In Receivables Prepayments And Deposits
IncreaseDecreaseInReceivablesPrepaymentsAndDeposits
|
905000 | |
| CY2016Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
32301000 | |
| CY2017 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
19731000 | |
| CY2017 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
15000 | |
| CY2017 | us-gaap |
Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
|
1822000 | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-44718000 | |
| CY2017 | us-gaap |
Proceeds From Interest Received
ProceedsFromInterestReceived
|
1342000 | |
| CY2017 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
494000 | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
64011000 | |
| CY2017 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
438000 | |
| CY2017 | us-gaap |
Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
|
15000 | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
423000 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
9.85 | |
| CY2019 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P3Y4M9D | |
| CY2019 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
326094 | |
| CY2018 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
64938 | |
| CY2017 | us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
70500000 | |
| CY2019 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
197000 | |
| CY2019 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
181000 | |
| CY2019 | us-gaap |
Lease Cost
LeaseCost
|
502000 | |
| CY2019Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
570000 | |
| CY2019Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
481000 | |
| CY2019Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
1051000 | |
| CY2019Q4 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
48000 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
1003000 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
556000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
336000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
978000 | |
| CY2018 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
700000 | |
| CY2017 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
700000 | |
| CY2019Q4 | nltx |
Stock Shares Authorized Net
StockSharesAuthorizedNet
|
100000000 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2897294 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
9.04 | |
| CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y11M15D | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
747162 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
8.71 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
5840538 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
5.11 | |
| CY2019 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y8M19D | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
1805043 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.80 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | |
| CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0280 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
6.24 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.90 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.84 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | |
| CY2019 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y25D | |
| CY2017 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0143 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0190 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
2.17 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
11.85 | |
| CY2019Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
8400000 | |
| CY2018Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
7800000 | |
| CY2019 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P3Y6M10D | |
| CY2018 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y9M14D | |
| CY2019Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
62000 | |
| CY2018Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
9000 | |
| CY2018Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
313000 | |
| CY2019Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2019Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
567000 | |
| CY2019 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-70959000 | |
| CY2018 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
70000 | |
| CY2018 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
25000000 | |
| CY2018 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-32624000 | |
| CY2017 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-51119000 | |
| CY2017 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
99000 | |
| CY2019 | dei |
Document Type
DocumentType
|
10-K | |
| CY2019 | nltx |
Acquisition Of Assets Net Cash Acquired
AcquisitionOfAssetsNetCashAcquired
|
191000 | |
| CY2019 | us-gaap |
Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
|
47716000 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
23537368 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
37996849 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
4016500 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
2.91 | |
| CY2019 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
326094 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
4.77 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
45037000 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
300000 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
1300000 | |
| CY2018 | nltx |
Non Refundable Up Front Payment Received
NonRefundableUpFrontPaymentReceived
|
25000000 | |
| CY2019 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5912538 | |
| CY2018 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2897294 | |
| CY2017 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2069167 | |
| CY2019Q3 | nltx |
Acquisitions Of Assets Cash Consideration For Fractional Shares
AcquisitionsOfAssetsCashConsiderationForFractionalShares
|
5000 | |
| CY2019Q3 | nltx |
Acquisitions Of Assets Transaction Costs
AcquisitionsOfAssetsTransactionCosts
|
3086000 | |
| CY2019Q3 | nltx |
Acquisitions Of Assets Consideration Transferred
AcquisitionsOfAssetsConsiderationTransferred
|
51578000 | |
| CY2019Q4 | nltx |
Finance Lease Liability Aggregate Purchase Price Of Asset
FinanceLeaseLiabilityAggregatePurchasePriceOfAsset
|
300000 | |
| CY2019 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
19000 | |
| CY2019 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
236000 | |
| CY2019 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
1182000 | |
| CY2019 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
9000 | |
| CY2019Q4 | us-gaap |
Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
|
66000 | |
| CY2019Q4 | us-gaap |
Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
|
60000 | |
| CY2019Q4 | us-gaap |
Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
|
60000 | |
| CY2019Q4 | us-gaap |
Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
|
59000 | |
| CY2019Q4 | us-gaap |
Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
|
245000 | |
| CY2019Q4 | us-gaap |
Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
|
37000 | |
| CY2019Q4 | us-gaap |
Finance Lease Liability
FinanceLeaseLiability
|
208000 | |
| CY2019Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
62000 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
| CY2019 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2019-12-31 | |
| CY2019 | dei |
Entity Registrant Name
EntityRegistrantName
|
Neoleukin Therapeutics, Inc. | |
| CY2019 | dei |
Security12b Title
Security12bTitle
|
Common Stock | |
| CY2019 | dei |
Trading Symbol
TradingSymbol
|
NLTX | |
| CY2019Q2 | dei |
Entity Public Float
EntityPublicFloat
|
24200000 | |
| CY2020Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
38373160 | |
| CY2019 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2019 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2019 | |
| CY2019 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2019 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001404644 | |
| CY2019 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2019 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
| CY2019 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
DE | |
| CY2019 | dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | |
| CY2019 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
| CY2019 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2019 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2019 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
| CY2019Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.000001 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2018Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.000001 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
37996849 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
23537368 | |
| CY2019 | us-gaap |
Interest Expense
InterestExpense
|
1000 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.006 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.008 | |
| CY2017 | us-gaap |
Interest Expense
InterestExpense
|
4000 | |
| CY2019 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
1517000 | |
| CY2019 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
7683000 | |
| CY2019 | us-gaap |
Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
|
10192700 | |
| CY2019 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
41000 | |
| CY2019 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
5525000 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.007 | |
| CY2018 | us-gaap |
Interest Expense
InterestExpense
|
4000 | |
| CY2018 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
1039000 | |
| CY2017 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
936000 | |
| CY2019 | us-gaap |
Profit Loss
ProfitLoss
|
-69442000 | |
| CY2018 | us-gaap |
Profit Loss
ProfitLoss
|
-31585000 | |
| CY2019 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
86216000 | |
| CY2019 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
5525000 | |
| CY2019 | us-gaap |
Interest Paid Net
InterestPaidNet
|
1000 | |
| CY2018 | us-gaap |
Interest Paid Net
InterestPaidNet
|
4000 | |
| CY2017 | us-gaap |
Interest Paid Net
InterestPaidNet
|
4000 | |
| CY2017 | us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
5995000 | |
| CY2017 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
468000 | |
| CY2017 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3839000 | |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
98887000 | |
| CY2018 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
602000 | |
| CY2018 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
4698000 | |
| CY2019 | us-gaap |
Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
|
15055000 | |
| CY2019 | nltx |
Preferred Stock Issued During Period Value Purchase Of Assets
PreferredStockIssuedDuringPeriodValuePurchaseOfAssets
|
33432000 | |
| CY2019 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
80691000 | |
| CY2019 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
1555000 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
2748000 | |
| CY2019Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
688000 | |
| CY2018Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
843000 | |
| CY2018Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
443000 | |
| CY2019Q4 | us-gaap |
Accounts Payable Trade Current
AccountsPayableTradeCurrent
|
1604000 | |
| CY2018Q4 | us-gaap |
Accounts Payable Trade Current
AccountsPayableTradeCurrent
|
702000 | |
| CY2019Q4 | nltx |
Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
|
944000 | |
| CY2018Q4 | nltx |
Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
|
3655000 | |
| CY2019Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1238000 | |
| CY2018Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
21000 | |
| CY2019Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
339000 | |
| CY2018Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
240000 | |
| CY2019Q4 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
300000 | |
| CY2019Q4 | nltx |
Percentage Of Increase In Lease Rent
PercentageOfIncreaseInLeaseRent
|
0.025 | |
| CY2019 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
105000 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
50000000 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2019 | nltx |
Common Stock Reserved For Issuance Description
CommonStockReservedForIssuanceDescription
|
Additionally, the number of shares of common stock reserved for issuance under the 2014 Plan will automatically increase on January 1 of each year for a period of up to 10 years, beginning on January 1, 2015 and ending on and including January 1, 2024, by 4% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the board of directors. | |
| CY2019Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.000001 | |
| CY2018Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.000001 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
0.000 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
-0.001 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
-0.036 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.006 | |
| CY2018 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-9108000 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0.248 | |
| CY2017 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-6425000 | |
| CY2019 | us-gaap |
Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
|
less than a 50% | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0.254 | |
| CY2019Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | |
| CY2019 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
-2129000 | |
| CY2017 | nltx |
Effective Income Tax Reconciliation Effect Of Tax Cuts And Jobs Act
EffectiveIncomeTaxReconciliationEffectOfTaxCutsAndJobsAct
|
0.046 | |
| CY2017 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-19000 | |
| CY2019 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-67313000 | |
| CY2018 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
-22477000 | |
| CY2017 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
-43758000 | |
| CY2019 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-69442000 | |
| CY2018 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-31585000 | |
| CY2017 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-50183000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
|
39574000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
|
40252000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
|
5347000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
|
5588000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
11062000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
9588000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
1831000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
1797000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
57814000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
57225000 | |
| CY2019 | nltx |
Effective Income Tax Rate Reconciliation At Federal And State Statutory Income Tax Rate Percent
EffectiveIncomeTaxRateReconciliationAtFederalAndStateStatutoryIncomeTaxRatePercent
|
0.21 | |
| CY2018Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
| CY2017 | nltx |
Tax Cuts And Jobs Act Of2017 Change In Tax Rate Deferred Tax Assets
TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssets
|
-2300000 | |
| CY2019 | us-gaap |
Income Tax Examination Description
IncomeTaxExaminationDescription
|
The Company currently files income tax returns in the United States and Canada, the jurisdictions in which the Company believes that it is subject to tax. Further, while the statute of limitations in each jurisdiction where an income tax return has been filed generally limits the examination period, as a result of loss carry-forwards, the limitation period for examination generally does not expire until several years after the loss carry-forwards are utilized. Other than routine audits by tax authorities for tax credits and tax refunds that the Company has claimed, the Company is not aware of any other material income tax examination currently in progress by any taxing jurisdiction. | |
| CY2019Q4 | nltx |
Stock Decrease Increase During Period Shares Conversion Of Common Stock To Prefunded Warrants
StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants
|
10925481 | |
| CY2019 | nltx |
Period Shares Reserved For Issuance Will Increase
PeriodSharesReservedForIssuanceWillIncrease
|
P10Y | |
| CY2019Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
7264000 | |
| CY2019 | nltx |
License And Collaboration Agreement Terms
LicenseAndCollaborationAgreementTerms
|
The license and collaboration agreement also included an upfront payment of $25.0 million and contractual milestones. | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2018Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2018Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2019Q3 | nltx |
Stock Conversion Ratio
StockConversionRatio
|
1 preferred stock = 100 common stock | |
| CY2019 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2019Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
0 | |
| CY2018Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
0 | |
| CY2016Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
144664000 | |
| CY2016Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest Adjusted Balance1
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1
|
144664000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
362000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
280000 | |
| CY2019 | nltx |
Stock Based Compensation Increase In Common Stock Issuance Percentage
StockBasedCompensationIncreaseInCommonStockIssuancePercentage
|
0.04 | |
| CY2019 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
| CY2019 | us-gaap |
Investment Income Net
InvestmentIncomeNet
|
1542000 | |
| CY2018 | us-gaap |
Investment Income Net
InvestmentIncomeNet
|
1563000 | |
| CY2017 | us-gaap |
Investment Income Net
InvestmentIncomeNet
|
998000 | |
| CY2019 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-16000 | |
| CY2018 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-75000 | |
| CY2018 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
1043000 | |
| CY2017 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
940000 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
|
4500000 | |
| CY2019 | nltx |
Other Non Operating Income And Expense Miscellaneous
OtherNonOperatingIncomeAndExpenseMiscellaneous
|
-8000 | |
| CY2018 | nltx |
Other Non Operating Income And Expense Miscellaneous
OtherNonOperatingIncomeAndExpenseMiscellaneous
|
-445000 | |
| CY2017 | nltx |
Other Non Operating Income And Expense Miscellaneous
OtherNonOperatingIncomeAndExpenseMiscellaneous
|
-39000 | |
| CY2019 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
1518000 | |
| CY2019 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
| CY2019 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
||
| CY2019 | nltx |
Stock Decrease Increase During Period Value Conversion Of Common Stock To Prefunded Warrants
StockDecreaseIncreaseDuringPeriodValueConversionOfCommonStockToPrefundedWarrants
|
||
| CY2019 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1. Nature of operations </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Neoleukin Therapeutics, Inc. (“Neoleukin” or “the Company”) is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using<div style="font-style:italic;display:inline;;font-style:italic;display:inline;"> de novo </div>protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. The Company’s lead product candidate, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NL-201,</div> is a combined <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-2</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-15</div> agonist designed to eliminate alpha receptor binding.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company commenced operations in Canada in December 2003. Aquinox Pharmaceuticals (Canada) Inc., a corporation formed under the Canada Business Corporations Act, is a wholly owned subsidiary of Aquinox Pharmaceuticals, Inc., a Delaware corporation formed in May 2007 (“Aquinox”). On August 8, 2019, upon the merger of Aquinox with Neoleukin Therapeutics, Inc. (“Former Neoleukin”) pursuant to an Agreement and Plan of Merger dated August 5, 2019, Former Neoleukin merged with a wholly owned subsidiary of Aquinox. Upon completion of the transaction, Aquinox was renamed Neoleukin Therapeutics, Inc. </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s head<div style="display:inline;"> </div>office is in Seattle, Washington. </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2019 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">(d) Use of estimates and assumptions </div></div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant areas requiring management estimates include valuation of stock options and restricted stock units, amortization and depreciation, determination of the fair values of assets and liabilities acquired in the acquisition of net assets of Former Neoleukin, accrual of expenses, <div style="letter-spacing: 0px; top: 0px;;display:inline;">determination of research and development costs, </div>valuation allowance for deferred income taxes, and contingencies. Actual results could differ from those estimates. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2019 | nltx |
Clinical Trial Accrual
ClinicalTrialAccrual
|
<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">(i) Clinical trial accruals </div></div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the process of preparing its consolidated financial statements, the Company is required to estimate expenses resulting from its obligations under contracts with vendors, consultants and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations which vary contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company reflects the appropriate clinical trial expenses in the consolidated financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the course of a clinical trial, the Company adjusts the rate of clinical trial expense recognition if actual results differ from estimates. The Company prepares estimates of accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known at that time. Although the Company does not expect the estimates to be materially different from amounts actually incurred, the Company’s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. The Company’s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2019 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">(r) Concentration of credit risk </div></div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents. Cash and cash equivalents are invested in accordance with the Company’s investment policy. The primary objective for the Company’s investment portfolio is the preservation of capital and maintenance of liquidity and includes guidelines on the quality of financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. </div></div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2019Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
659000 | |
| CY2019Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
92000 | |
| CY2019 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
||
| CY2019Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
||
| CY2019Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
||
| CY2019Q4 | us-gaap |
Purchase Obligation
PurchaseObligation
|
800000 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.210 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.210 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.350 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.000 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
-0.006 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
|
-0.002 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
|
-0.043 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
|
0.079 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
|
0.144 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
|
0.000 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
|
0.000 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
|
0.026 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
|
0.028 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
|
0.020 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
-0.014 | |
| CY2019 | nltx |
Risk And Uncertainties
RiskAndUncertainties
|
<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">(t) Risks and uncertainties </div></div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to numerous risks and uncertainties. These risks, among others, included the following: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;"> </td><td style="text-align:left;;vertical-align:top;;width:3%;">•</td><td style="font-family: "times new roman";;vertical-align:top;;width:1%;"> </td><td style="font-size: 10pt;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Company has no source of recurring revenue, has an accumulated deficit of $299.5 million as of December 31, 2019, may never become profitable and may incur substantial and increasing net losses for the foreseeable future as it continues its research and development programs; </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;"> </td><td style="text-align:left;;vertical-align:top;;width:3%;">•</td><td style="font-family: "times new roman";;vertical-align:top;;width:1%;"> </td><td style="font-size: 10pt;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Company is likely to require additional capital to finance its operations which may not be available to it on acceptable terms, or at all; </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;"> </td><td style="text-align:left;;vertical-align:top;;width:3%;">•</td><td style="font-family: "times new roman";;vertical-align:top;;width:1%;"> </td><td style="font-size: 10pt;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Company’s success is primarily dependent on the successful development, regulatory approval and commercialization of its drug product candidates; </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;"> </td><td style="text-align:left;;vertical-align:top;;width:3%;">•</td><td style="font-family: "times new roman";;vertical-align:top;;width:1%;"> </td><td style="font-size: 10pt;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Company is subject to regulatory approval processes that are lengthy, time consuming and inherently unpredictable; the Company may not be able to obtain approval for any drug product candidates from the U.S. Food and Drug Administration, or FDA, or foreign regulatory authorities; </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;"> </td><td style="text-align:left;;vertical-align:top;;width:3%;">•</td><td style="font-family: "times new roman";;vertical-align:top;;width:1%;"> </td><td style="font-size: 10pt;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Company’s intellectual property rights may be subject to claims by third parties and can be difficult and costly to protect; </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;"> </td><td style="text-align:left;;vertical-align:top;;width:3%;">•</td><td style="font-family: "times new roman";;vertical-align:top;;width:1%;"> </td><td style="font-size: 10pt;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Company may not be able to recruit or retain key employees, including its senior management team; </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;"> </td><td style="text-align:left;;vertical-align:top;;width:3%;">•</td><td style="font-family: "times new roman";;vertical-align:top;;width:1%;"> </td><td style="font-size: 10pt;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Company depends on the performance of third parties, including contract research organizations and third-party manufacturers; and </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;"> </td><td style="text-align:left;;vertical-align:top;;width:3%;">•</td><td style="font-family: "times new roman";;vertical-align:top;;width:1%;"> </td><td style="font-size: 10pt;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Company faces competition from other pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions, among others. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
447000 | |
| CY2019Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
146000 | |
| CY2018Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
6000 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.00 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.00 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.00 | |
| CY2019 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
340000 | |
| CY2018 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
289000 | |
| CY2017 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
360000 | |
| CY2019 | nltx |
Receivables Prepayments And Deposits Acquired Through The Issuance Of Common Stock
ReceivablesPrepaymentsAndDepositsAcquiredThroughTheIssuanceOfCommonStock
|
560000 | |
| CY2019 | nltx |
Property Equipment And Intangibles Acquired Through The Issuance Of Common Stock
PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock
|
1693000 | |
| CY2019 | us-gaap |
Liabilities Assumed1
LiabilitiesAssumed1
|
1673000 | |
| CY2017 | nltx |
Increase Decrease In Accruals For Purchase Of Property And Equipment
IncreaseDecreaseInAccrualsForPurchaseOfPropertyAndEquipment
|
-77000 | |
| CY2017 | nltx |
Share Issuance Expenditures Incurred But Not Yet Paid
ShareIssuanceExpendituresIncurredButNotYetPaid
|
-30000 | |
| CY2019 | us-gaap |
Depreciation
Depreciation
|
200000 | |
| CY2018 | us-gaap |
Depreciation
Depreciation
|
300000 | |
| CY2017 | us-gaap |
Depreciation
Depreciation
|
400000 | |
| CY2018Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
||
| CY2019 | nltx |
Effective Income Tax Rate Reconciliation Expiration Of Net Operating Losses
EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLosses
|
0.054 | |
| CY2019 | us-gaap |
Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
|
P3Y | |
| CY2019Q4 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P3Y3M29D | |
| CY2019Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P1Y9M29D | |
| CY2019Q4 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.0711 | |
| CY2019Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0537 |
